This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of entacapone
PDMED_ENTACAPONE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
315 |
4. Check minimum number of events
Min. number of events
3
|
315 |
5. Include endpointsNone |
315 |
6. Filter based on genotype QC (FinnGen only) |
306 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of entacapone
based on the number of shared cases.
Similar with more cases:
- Use of levodopa decarboxylase inhibitor
- Parkinson's disease
- Parkinson's disease, excluding more controls
- Parkinson's disease, including avohilmo
- Extrapyramidal and movement disorders
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 306 | 109 | 197 |
| Unadjusted period prevalence (%) | 0.07 | 0.04 | 0.09 |
| Median age at first event (years) | 69.26 | 67.11 | 70.45 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 315
- Matched controls
- 3150
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G20
ICD-10 Finland
Parkinson disease
4870.3
307.7
312
60
N04BX02
ATC
entacapone; oral
+∞
307.7
315
*
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
5412.0
307.7
312
53
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
+∞
307.7
315
82
N04BD01
ATC
selegiline; oral
397.4
307.7
226
20
N04BA03
ATC
levodopa, decarboxylase inhibitor and COMT inhibitor; oral
716.3
307.7
219
10
N04BC05
ATC
pramipexole; oral
43.0
265.1
209
138
N87
ICPC
Parkinsonism
81.2
219.4
121
24
N04BB01
ATC
amantadine; oral
96.6
161.1
85
12
N04BC04
ATC
ropinirole; oral
287.9
116.3
112
6
N04BD02
ATC
rasagiline; oral
243.4
113.9
111
7
F02.39*G20
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
242.8
102.1
100
6
193
Kela drug reimbursment
Rasagiline
270.5
97.5
95
5
N05AH04
ATC
quetiapine; oral
8.7
79.4
144
279
N06DA03
ATC
rivastigmine; oral, transdermal
11.9
77.0
91
104
N04AA02
ATC
biperiden; systemic
33.1
72.6
48
17
N03AE01
ATC
clonazepam; systemic
12.3
68.6
77
81
G02CB01
ATC
bromocriptine; systemic
169.5
54.8
56
*
N04BC02
ATC
pergolide; oral
310.1
52.8
52
*
N04BC09
ATC
rotigotine; transdermal
519.2
46.5
45
*
XA800
NOMESCO Finland
Neuropsychological investigation
13.7
41.9
41
34
R25.1
ICD-10 Finland
Tremor, unspecified
13.8
39.1
38
31
AAG20
NOMESCO Finland
Stereotactic intracranial implantation of electrodes
82.5
39.0
43
6
N04BC06
ATC
cabergoline; oral
221.7
38.7
39
*
AEA50
NOMESCO Finland
Adjustment of implanted neurostimulator
88.8
35.7
39
5
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
6.0
28.6
56
109
AEA00
NOMESCO Finland
Replacement of impulse generator of stimulation device in the nervous system
44.2
26.4
32
8
A06AD11
ATC
lactulose; oral
3.7
26.0
120
454
Z2445
NOMESCO Finland
Psychologist
9.9
24.2
29
32
307
Kela drug reimbursment
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
4.8
24.0
61
149
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
90.3
23.0
25
*
N04BC01
ATC
bromocriptine; oral
+∞
22.1
21
*
N04BX01
ATC
tolcapone; oral
+∞
17.9
17
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
20.8
17.2
25
13
H02AA02
ATC
fludrocortisone; oral
14.5
16.8
28
21
F02.39
ICD-10 Finland
Dementia in Parkinson's disease without information on additional symptoms
89.6
15.7
17
*
G21.9
ICD-10 Finland
Secondary parkinsonism, unspecified
24.9
15.3
21
9
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.9
14.1
82
341
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
2.5
13.8
149
839
N05BA04
ATC
oxazepam; oral
2.5
13.1
111
556
S01.0
ICD-10 Finland
Open wound of scalp
3.4
12.6
51
171
N04BX04
ATC
opicapone; oral
135.2
12.5
13
*
G04BD12
ATC
mirabegron; oral
3.0
12.5
64
247
I95.1
ICD-10 Finland
Orthostatic hypotension
4.0
12.3
37
101
J69.0
ICD-10 Finland
Pneumonitis due to food and vomit
6.0
12.1
22
39
XKD06
NOMESCO Finland
Physiologic investigation of micturition
5.2
11.9
25
51
ZXM20
NOMESCO Finland
Intraoperative use of computerised tomography
17.3
11.8
18
11
G25.9
ICD-10 Finland
Extrapyramidal and movement disorder, unspecified
15.8
11.4
18
12
SPAT1231
SPAT
Assessment of adjustments needed in living environment
5.8
11.3
21
38
N06AX11
ATC
mirtazapine; oral
2.3
11.3
122
674
C07AA05
ATC
propranolol; systemic
2.8
11.3
65
267
R4130
NOMESCO Finland
Speech therapy
6.0
11.1
20
35
R13
ICD-10 Finland
Dysphagia
3.4
10.6
41
133
N19
ICPC
Speech disorder
14.9
10.6
17
12
R53
ICD-10 Finland
Malaise and fatigue
2.3
10.6
104
549
N06AB04
ATC
citalopram; systemic
2.4
10.5
88
433
SPAT1224
SPAT
Implementation of speech therapy rehabilitation plan
16.8
10.5
16
10
AA1AD
NOMESCO Finland
CT of head and brain
2.3
10.4
116
645
R47.1
ICD-10 Finland
Dysarthria and anarthria
11.9
10.2
18
16
SPAT1229
SPAT
Assessment of need for aid
3.1
10.2
47
170
N06AB10
ATC
escitalopram; oral
2.7
9.8
61
259
N30.0
ICD-10 Finland
Acute cystitis
2.7
9.8
60
253
S72.0
ICD-10 Finland
Fracture of neck of femur
3.2
9.6
40
136
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.6
9.5
23
53
N05AH02
ATC
clozapine; systemic
18.2
9.5
14
8
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
5.3
9.2
19
38
N30.9
ICD-10 Finland
Cystitis, unspecified
3.5
9.2
33
102
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.4
9.1
72
343
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
4.1
8.9
25
65
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.4
8.9
75
368
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.2
8.7
37
127
JX1LA
NOMESCO Finland
Kinetic X-ray of alimentary tract with pictures
51.4
8.7
10
*
ZXE30
NOMESCO Finland
More than five and less than seven hours
4.1
8.6
24
62
XF606
NOMESCO Finland
Ortostatic test
28.4
8.5
11
*
N04AA01
ATC
trihexyphenidyl; oral
+∞
8.4
8
*
N05CD07
ATC
temazepam; oral
2.3
8.1
71
353
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
11.2
7.9
14
13
R1250
NOMESCO Finland
Evaluation of functional capability
6.7
7.8
19
30
Z02.4
ICD-10 Finland
Examination for driving licence
0.3
7.8
27
705
N04BC07
ATC
apomorphine; parenteral
+∞
7.3
7
*
AAW01
NOMESCO Finland
Implantation of intracranial stimulation device
+∞
7.3
7
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.1
7.3
32
112
AA1BD
NOMESCO Finland
Extensive CT of head and brain
4.7
7.3
17
38
I10
ICD-10 Finland
Essential (primary) hypertension
0.5
7.2
125
1756
N29
ICPC
Neurological sympt/complt other
8.1
6.7
14
18
N06AX03
ATC
mianserin; oral
3.2
6.7
27
90
D21
ICPC
Swallowing problem
7.1
6.6
15
22
UKC02
NOMESCO Finland
Cystoscopy
2.1
6.5
77
428
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.2
6.5
61
310
N03AX12
ATC
[U] gabapentin; oral
2.2
6.4
56
277
C10AA07
ATC
rosuvastatin; oral
0.4
6.4
25
622
M48.0
ICD-10 Finland
Spinal stenosis
2.2
6.3
59
299
C10AX09
ATC
ezetimibe; oral
0.2
6.3
7
310
C10AA05
ATC
atorvastatin; oral
0.5
6.3
63
1073
YX8AD
NOMESCO Finland
Stereotactic CT examination for dose design of radiotherapy
27.3
6.3
8
*
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.0
6.1
17
44
ZXE10
NOMESCO Finland
More than one and less than three hours
1.8
6.0
123
818
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.0
6.0
27
96
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
119
1906
0.40
14.02
3.2
4.3
1.22
1.26
mmol/l
0.31
105
1676
126
1961
0.40
13.64
3.4
4.8
1.37
1.43
mmol/l
0.69
110
1737
128
1977
0.41
13.55
3.4
4.8
4.23
4.40
mmol/l
1.61
114
1772
142
2041
0.45
11.13
3.5
5.5
2.42
2.54
mmol/l
1.12
122
1803
139
1985
0.46
10.10
5.1
6.6
40.02
41.51
mmol/mol
1.01
129
1794
148
2026
0.49
8.72
3.7
5.1
5.83
6.16
mmol/l
3.13
130
1778
169
2188
0.51
7.85
7.8
11.1
14.27
23.65
u/l
17.19
148
2075
33
732
0.39
6.55
3.2
3.8
4.06
10.15
mg/mmol
1.81
25
462
185
2263
0.56
5.82
29.8
25.9
38.42
39.16
%
0.76
168
2076
185
2263
0.56
5.82
29.5
25.7
4.31
4.39
e12/l
1.25
177
2168
79
1229
0.52
5.81
2.3
3.1
56.16
54.97
u/l
0.03
73
1114
185
2262
0.56
5.79
29.7
25.8
243.62
236.21
e9/l
0.96
180
2179
152
1953
0.57
5.59
20.8
17.0
86.19
71.72
ml/min/173m2
16.20
124
1608
148
1893
0.59
5.06
4.1
4.6
1.91
2.04
mu/l
0.65
135
1644
18
63
2.97
4.13
3.3
4.6
27.40
33.35
mg/l
0.37
13
41
122
1594
0.62
4.12
3.1
4.2
12.02
15.22
mm/h
1.74
115
1427
68
1019
0.58
3.95
4.7
5.3
5.41
3.79
ug/l
0.30
61
882
139
1717
0.66
3.27
5.0
7.6
83.87
80.58
u/l
0.34
126
1593
179
2100
0.66
3.25
21.7
17.9
29.63
26.75
mg/l
0.48
155
1738
61
903
0.60
3.25
3.0
3.2
1608.77
1978.60
ng/l
0.27
52
766
35
602
0.53
3.20
3.6
2.8
15008.83
9310.38
umol/l
0.23
29
491
95
1228
0.68
2.59
4.1
6.1
10.33
11.91
umol/l
1.37
89
1154
122
1505
0.69
2.58
3.3
3.8
14.55
15.10
pmol/l
1.37
107
1298
6
11
5.54
2.55
1.3
1.8
—
—
—
0
0
58
404
1.53
2.15
3.5
2.9
0.91
1.07
e6/l
0.25
31
234
56
388
1.54
2.13
3.6
3.1
2.20
1.43
e6/l
0.33
29
223
64
864
0.67
2.10
2.7
2.7
150.55
152.71
ug/l
0.02
56
770
82
1044
0.71
1.91
4.5
4.4
37.30
46.30
ng/l
0.25
64
819
15
284
0.50
1.86
2.7
4.3
2.91
51.14
ug/l
—
8
246
9
192
0.45
1.80
1.1
1.3
—
—
—
0
0
9
191
0.46
1.80
2.3
3.3
4.91
5.17
kpa
—
9
183
100
1219
0.74
1.74
9.2
8.9
4.55
4.36
e9/l
0.24
77
1056
44
303
1.53
1.73
2.3
1.8
—
—
—
0
0
107
873
1.34
1.65
3.9
3.4
—
—
—
0
0
14
259
0.52
1.63
2.3
2.6
3.79
6.90
ug/l
1.67
14
225
63
811
0.72
1.52
4.4
4.6
15.20
21.73
%
3.08
25
423
0
44
0.00
1.52
0.0
1.1
—
30.15
—
0
37
43
305
1.47
1.49
2.3
1.8
—
—
—
0
0
43
575
0.71
1.30
2.9
3.1
0.65
0.88
ug/l
1.74
30
400
84
687
1.30
1.25
4.3
3.3
0.28
0.50
e6/l
1.34
64
530
0
35
0.00
1.16
0.0
1.1
—
—
—
0
0
53
671
0.75
1.13
2.8
2.1
3.41
3.28
mg/l
0.08
43
557
76
622
1.29
1.12
1.9
1.7
20.90
20.65
nmol/l
0.05
66
507
44
561
0.75
0.99
2.1
1.8
332.84
12809429.78
pmol/l
0.50
37
445
0
30
0.00
0.98
0.0
1.6
—
—
—
0
0
0
30
0.00
0.98
0.0
1.4
—
267.71
—
0
30
0
31
0.00
0.97
0.0
1.5
—
—
—
0
0
0
31
0.00
0.97
0.0
1.5
—
—
—
0
0
0
31
0.00
0.97
0.0
1.5
—
—
—
0
0
0
31
0.00
0.97
0.0
1.5
—
—
—
0
0
0
31
0.00
0.97
0.0
4.4
—
—
—
0
0
0
32
0.00
0.95
0.0
1.5
—
—
—
0
0
0
32
0.00
0.95
0.0
1.5
—
—
—
0
0
36
466
0.74
0.90
1.5
1.7
1.21
1.46
mg/l
0.31
30
378
73
617
1.24
0.83
4.9
4.4
0.00
0.00
estimate
-0.00
26
208
0
24
0.00
0.79
0.0
1.8
—
—
—
0
0
0
24
0.00
0.79
0.0
1.8
—
—
—
0
0
0
24
0.00
0.79
0.0
1.8
—
—
—
0
0
0
24
0.00
0.79
0.0
1.8
—
—
—
0
0
0
26
0.00
0.79
0.0
2.7
—
—
—
0
0
37
291
1.31
0.75
5.3
3.9
—
—
—
0
0
95
1074
0.83
0.75
5.1
4.2
34.71
34.51
g/l
0.13
90
986
21
153
1.40
0.69
2.0
1.7
—
—
—
0
0
164
1528
1.15
0.60
6.9
4.9
9268.93
3600.69
e6/l
0.45
15
39
0
22
0.00
0.59
0.0
1.9
—
—
—
0
0
111
1216
0.87
0.57
5.1
6.3
1.21
1.21
mmol/l
0.15
99
998
129
1396
0.87
0.56
4.9
5.0
6.30
6.87
mmol/l
4.39
124
1318
71
802
0.85
0.55
3.5
3.2
2.31
2.34
mmol/l
1.02
64
696
117
1072
1.15
0.53
5.5
4.2
0.00
0.00
estimate
0.50
29
239
23
290
0.78
0.51
6.7
8.5
—
—
—
0
0
95
860
1.15
0.51
5.9
4.5
—
—
—
0
0
117
1268
0.88
0.51
11.5
18.5
1.26
1.39
inr
0.90
27
377
16
211
0.75
0.49
2.8
2.8
3.88
4.25
kpa
0.44
16
201
116
1068
1.14
0.49
7.5
5.6
0.00
0.00
estimate
-0.00
22
215
117
1083
1.13
0.45
5.5
4.2
0.00
0.00
estimate
-0.00
25
210
33
388
0.83
0.41
2.5
3.0
0.80
0.82
mmol/l
0.43
33
355
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
37
317
1.19
0.40
4.9
6.6
2.24
1.43
mmol/l
0.57
28
260
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
485.00
—
0
11
0
19
0.00
0.39
0.0
1.0
—
36.53
—
0
10
20
244
0.81
0.36
2.5
3.8
6.00
5.80
kpa
0.30
20
235
5
80
0.62
0.35
1.2
1.3
—
—
—
0
0
49
435
1.15
0.35
2.4
1.8
—
—
—
0
0
6
90
0.66
0.33
3.5
2.7
—
—
—
0
0
7
98
0.71
0.31
2.0
3.0
4.49
4.25
pmol/l
—
7
84
7
55
1.28
0.30
1.6
1.4
—
—
—
0
0
7
55
1.28
0.30
1.6
1.4
—
—
—
0
0
14
173
0.80
0.29
4.4
2.7
80.67
57.29
ml/min/173m2
—
6
72
7
57
1.23
0.29
1.0
1.4
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
6
83
0.72
0.24
1.8
2.0
0.96
0.36
u/ml
—
6
41
6
83
0.72
0.24
1.2
1.0
—
—
—
0
0
106
1115
0.93
0.24
4.5
5.8
1.20
1.21
mmol/l
0.34
99
1003
16
189
0.84
0.23
1.4
1.5
—
—
—
0
0
5
39
1.29
0.23
1.8
1.3
24.20
208.88
e6/l
—
5
33
13
156
0.83
0.22
1.4
2.1
10.95
12.63
nmol/l
0.25
13
138
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
4.1
—
71.40
—
0
10
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
6
48
1.25
0.20
1.2
1.4
—
—
—
0
0
52
559
0.92
0.20
1.9
2.4
—
—
—
0
0
18
156
1.16
0.19
1.3
1.4
—
—
—
0
0
5
69
0.72
0.17
1.2
1.2
—
—
—
0
0
5
69
0.72
0.17
1.2
1.2
—
—
—
0
0
6
78
0.76
0.15
1.0
1.3
—
—
—
0
0
9
80
1.13
0.15
2.1
1.6
—
—
—
0
0
46
489
0.93
0.14
2.4
3.1
2.46
2.46
mmol/l
0.05
39
425
84
869
0.95
0.11
2.0
2.2
68.21
78.61
nmol/l
3.08
72
739
56
581
0.96
0.08
1.7
1.8
1246.34
1198.04
nmol/l
0.13
47
422
5
62
0.80
0.08
1.2
1.6
—
—
—
0
0
5
63
0.79
0.08
1.2
1.6
—
—
—
0
0
32
336
0.95
0.07
4.4
6.2
106.19
103.88
mmol/l
1.20
32
336
9
105
0.85
0.06
1.1
2.6
—
—
—
0
0
14
149
0.94
0.03
1.1
1.4
—
—
—
0
0
100
1013
0.98
0.03
2.4
2.1
79.99
93.12
pmol/l
3.49
75
519
102
1030
0.99
0.02
2.4
2.6
—
—
—
0
0
49
482
1.02
0.01
3.3
3.8
63.38
214.50
ng/l
1.73
39
422
22
226
0.97
0.00
2.4
3.1
115.71
231.97
ng/l
2.14
17
199
22
226
0.97
0.00
4.0
6.6
1.02
1.32
mmol/l
1.22
22
220
93
927
1.00
0.00
2.9
2.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
1066.67
—
0
9
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
10.02
—
0
6
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
7
70
1.00
-0.00
2.1
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
1.17
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
28.67
—
0
6
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_ENTACAPONE – Use of entacapone
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).